The "polarization is the problem" narrative to me is bad because it implies the status quo was a stable and acceptable set of trade-offs. It's the equivalent of a pollyanna "why can't we all get along" but the we in question is white supremacy and its targets.
More from Machine learning
Starting a new project using #Angular? Here is a list of all the stuff i use to launch my projects the fastest i can.
A THREAD 👇
Have you heard about Monorepo? I created one with all my Angular (and Nest) projects using https://t.co/aY5llDtXg8.
I can share A LOT of code with it. Ex: Everytime i start a new project, i just need to import an Auth lib, that i created, and all Auth related stuff is set up.
Everyone in the Angular community knows about https://t.co/kDnunQZnxE. It's not the most beautiful component library out there, but it's good and easy to work with.
There's a bunch of state management solutions for Angular, but https://t.co/RJwpn74Qev is by far my favorite.
There's a lot of boilerplate, but you can solve this with the built-in schematics and/or with your own schematics
Are you not using custom schematics yet? Take a look at this:
https://t.co/iLrIaHVafm
https://t.co/3382Tn2k7C
You can automate all the boilerplate with hundreds of files associates with creating a new feature.
A THREAD 👇
Have you heard about Monorepo? I created one with all my Angular (and Nest) projects using https://t.co/aY5llDtXg8.
I can share A LOT of code with it. Ex: Everytime i start a new project, i just need to import an Auth lib, that i created, and all Auth related stuff is set up.
Everyone in the Angular community knows about https://t.co/kDnunQZnxE. It's not the most beautiful component library out there, but it's good and easy to work with.
There's a bunch of state management solutions for Angular, but https://t.co/RJwpn74Qev is by far my favorite.
There's a lot of boilerplate, but you can solve this with the built-in schematics and/or with your own schematics
Are you not using custom schematics yet? Take a look at this:
https://t.co/iLrIaHVafm
https://t.co/3382Tn2k7C
You can automate all the boilerplate with hundreds of files associates with creating a new feature.
Thanks for this incredibly helpful analysis @dgurdasani1
Two questions. 1/ Does this summarise the AZ published data :
The plan is to extend the time interval for all age groups despite it being largely untested on the over 55yrs, although the full data is not yet published
Do we have the actual numbers of over 55yr olds given a 2nd dose at c12 weeks and the accompanying efficacy data?
Not to mention the efficacy data of the full first dose over that same period?
I’d quite like to know whether I am to be a guinea pig & the ongoing risks to manage
You attached photos of excerpts from a paper. Could you attach the link?
Re Pfizer. As I understand it the most efficacious interval for dosing was investigated at the start of the trial.
Here’s the link to the
I’ve got to say that this way of making and announcing decisions is not inspiring confidence in me and I am very pro vaccination as a matter of principle, not least because my brother caught polio before vaccinations available.
Two questions. 1/ Does this summarise the AZ published data :
The plan is to extend the time interval for all age groups despite it being largely untested on the over 55yrs, although the full data is not yet published
SUMMARY: the Oxford/Astra trial examined dosing with gaps between 4-12 wks- although longer gaps appear to be limited mostly to younger participants. There was no difference reported in published data between these & efficacy from the 1st dose seems high for severe disease.
— Deepti Gurdasani (@dgurdasani1) December 31, 2020
Do we have the actual numbers of over 55yr olds given a 2nd dose at c12 weeks and the accompanying efficacy data?
Not to mention the efficacy data of the full first dose over that same period?
I’d quite like to know whether I am to be a guinea pig & the ongoing risks to manage
You attached photos of excerpts from a paper. Could you attach the link?
Re Pfizer. As I understand it the most efficacious interval for dosing was investigated at the start of the trial.
Discussions of 1 vs 2 doses suggest many are not aware of Pfizer's trials which evaluated 1 vs 2 dose immunogenicity, assessed multiple formulations (BNT162b1 BNT162b2 etc) & conducted dose-ranging in both young & old adults at the start. Saw "clear benefit of booster at day 21" pic.twitter.com/mpyxu9xFSF
— Dr Nicole E Basta (@IDEpiPhD) December 31, 2020
Here’s the link to the
I’ve got to say that this way of making and announcing decisions is not inspiring confidence in me and I am very pro vaccination as a matter of principle, not least because my brother caught polio before vaccinations available.